Edupression

Overview
Edupression is an Austrian digital-therapeutic company, founded in 2018 in Klosterneuburg (Lower Austria) by Daniel Amann and Prof. Dr. Lukas Pezawas and operated under the legal entity SOFY GmbH. Its product, edupression.com, is a CE-certified, prescription-eligible digital psychotherapy programme delivered as a mobile app and web app for patients with unipolar depression and burnout, based on cognitive-behavioural-therapy elements combined with structured psychoeducation and mood tracking. Edupression was co-developed with the Medical University of Vienna and its efficacy has been evaluated in a series of randomized controlled trials. Edupression has been publicly reported to be listed permanently in Germany's Digitale Gesundheitsanwendungen (DiGA) directory for prescription digital therapeutics.

Why this entity matters
Edupression is a T2-plus reference entity for the Austrian digital-health, medical-device and cross-border DACH-DiGA reimbursement narrative for four reasons. First, unipolar depression is one of the highest-burden non-communicable disease clusters in the DACH region, with well-documented and structural shortages of licensed psychotherapy capacity in both Germany and Austria, and prescription-eligible digital therapeutics are one of the emerging clinical and reimbursement pathways to close the treatment-access gap. Second, Edupression is one of a small number of Austrian-founded digital therapeutics to have been evaluated in a randomized controlled trial with an active sham control, an unusually rigorous design for the digital-therapeutic category. Third, Edupression is a canonical example of the cross-border DiGA reimbursement pathway: an Austrian-headquartered digital therapeutic that clears German medical-device and DiGA-directory requirements and thereby becomes prescribable and reimbursable inside Germany, one of the world's largest digital-health reimbursement markets. Fourth, Edupression's academic anchor at the Medical University of Vienna - one of the German-speaking world's leading psychiatry departments - links the company to one of the most systemically important clinical-research hubs in the DACH region.

Company history and product
Edupression was founded in 2018 in Klosterneuburg (Lower Austria) by Daniel Amann and Prof. Dr. Lukas Pezawas and operates under the legal entity SOFY GmbH. Edupression's product, edupression.com, is a digital psychotherapy programme for adults with unipolar depression or burnout, based on cognitive-behavioural-therapy elements combined with structured psychoeducation, symptom checking and mood tracking. Users take a symptom-based intake assessment that stratifies them into mild-to-moderate depression categories, and the programme is designed to help reduce depressive symptoms, improve treatment adherence, improve remission rates and reduce relapse risk in mild-to-moderately ill patients. The programme was co-developed with the Medical University of Vienna, one of the most clinically influential psychiatry departments in the German-speaking world, and its efficacy has been evaluated in a series of randomized controlled trials, including a randomized controlled trial with an active sham control reported by Preiss, Pezawas and co-authors and preprinted on SSRN, along with clinicaltrials.gov studies NCT04839822 (efficacy in depressive patients) and NCT04843462 (add-on therapy for therapy-resistant depression treated with nasal esketamine). Edupression has been publicly reported to hold CE certification as a medical device and to be listed permanently in Germany's Digitale Gesundheitsanwendungen (DiGA) directory, meaning that a German-licensed physician can prescribe edupression and German statutory health insurance funds reimburse the treatment; readers should verify current DiGA-directory status against the German Federal Institute for Drugs and Medical Devices (BfArM) DiGA-Verzeichnis before acting on this for time-sensitive use. Publicly available funding information at the time of research is limited; secondary sources describe the company as unfunded or bootstrapped, with academic and public-innovation-programme support.

Role in the DACH startup and technology ecosystem
Edupression sits at the intersection of three DACH themes. First, it is one of the most-cited Austrian digital-therapeutic companies of the last cohort of European medical-device digital-health startups, and one of a small number of Austrian ventures to have secured a permanent German DiGA listing. Second, it is a canonical example of the cross-border DACH digital-health reimbursement pathway - Austria-founded, Germany-reimbursed - which is one of the structural go-to-market pathways for Austrian and Swiss digital-health startups. Third, its academic anchor at the Medical University of Vienna links it to a systemically important clinical-research hub for the German-speaking psychiatry community, and its founder team combines a clinical principal investigator (Prof. Dr. Lukas Pezawas) with an operating entrepreneur (Daniel Amann), a pattern common to successful clinical-grade digital therapeutics.

Selected relationships and affiliations
Founders: Daniel Amann (operating entrepreneur); Prof. Dr. Lukas Pezawas (clinical principal investigator, Medical University of Vienna psychiatry department). Legal entity: SOFY GmbH. Headquarters: Klosterneuburg (Lower Austria), Austria. Academic partner: Medical University of Vienna. Clinical evidence: randomized controlled trial with active sham control (SSRN preprint, Preiss / Pezawas and co-authors); ClinicalTrials.gov study NCT04839822; ClinicalTrials.gov study NCT04843462. Regulatory: CE certification as a medical device; permanent listing in Germany's DiGA directory (per secondary sources; verify against BfArM DiGA-Verzeichnis for current status). Ecosystem support: Lower Austrian innovation and public-health-innovation programmes (per brutkasten and IOEB). Publicly reported investors: not clearly identified in public sources at the time of research; company reported as unfunded or bootstrapped in secondary databases; no `has_lead_investor` edge emitted. Related Startuprad.io entities: DACH digital-health coverage and Medical University of Vienna clinical-research references.

Startuprad.io relevance
Edupression is a T2 reference entity for Startuprad.io's Austrian digital-health, DACH DiGA-reimbursement and mental-health-technology coverage. Startuprad.io has two verified tagged references to Edupression, both dedicated founder-interview coverage of the company's prescription digital-therapeutic model, positioning Edupression alongside Startuprad.io's coverage of Kranus Health and other DACH digital-therapeutic companies.

Public source context
This profile draws on Edupression's own website https://edupression.com , the edupression professionals page https://edupression.com/en/professionals/edupression-at-a-glance/ , the brutkasten profile of edupression as a Lower Austrian startup https://brutkasten.com/artikel/edupression-startup-aus-noe-entwickelt-digitales-depressions-therapieprogramm , the Tracxn company profile https://tracxn.com/d/companies/edupression/__yhBNpcOb1G9GywMMreonqcTDnhT6uR7wmz5CdejUhrs , the LinkedIn company page https://www.linkedin.com/company/edupressioncom , the SSRN preprint of the randomized controlled trial by Preiss, Pezawas and co-authors https://dx.doi.org/10.2139/ssrn.5213394 , the ClinicalTrials.gov entries https://clinicaltrials.gov/study/NCT04839822 and https://clinicaltrials.gov/study/NCT04843462 , the IOEB innovation-marketplace listing https://www.ioeb-innovationsplattform.at/en/innovation-marketplace/detail/digitales-therapieprogramm-fuer-depressive-patienten/ , and the Google Play listing for edupression.com https://play.google.com/store/apps/details?id=com.proappdev.edupression_web_mobile_app .

Startuprad.io coverage of Edupression

Edupression appears in the following Startuprad.io interviews, news and analysis.

Meet Edupression a Vienna-based App on Prescription — Founder Interview
Published: 15 March 2026
Last updated: 29 August 2026
Coverage type: Interview
https://www.startuprad.io/post/meet-edupression-a-vienna-based-app-on-prescription-founder-interview

Meet Edupression a Vienna-Based App on Prescription
Published: 13 October 2021
Last updated: 14 August 2026
Coverage type: Interview
https://www.startuprad.io/post/meet-edupression-a-vienna-based-app-on-prescription

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

Canonical record: https://www.startuprad.io/entities/edupression